Hair loss is such a common experience that many people go through, but it can seem like it hits us out of nowhere. There are ...

BOSTON and LAUSANNE, Switzerland, March 27, 2025 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces that the first patient has been dosed ...

Unique siRNA platform, developed with Nobel Prize Laureate Craig Mello, offers potential for treating multiple dermatology indications ALY-101 is formulated as an intradermal injectable for the ...

Unique siRNA platform, developed with Nobel Prize Laureate Craig Mello, offers potential for treating multiple dermatology indications ALY-101 is formulated as an intradermal injectable for the ...

Significantly more adolescent patients receiving baricitinib had hair regrowth compared with patients receiving placebo.

On January 28, 2025, the Company received clearance of its IND from the FDA to initiate a first-in-human Phase 1 dose ...

Alopecia is the general medical term for hair loss, which can come in different forms and severities. Hair loss is a common ...

Q4 2024 Earnings Call Transcript March 27, 2025 STRATA Skin Sciences, Inc. misses on earnings expectations. Reported EPS is $ ...

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

Last week the Edinburgh Cancer Centre begun treating prostate cancer patients within the framework of the so-called Precision Study. Patients receive only three radiation doses, with the Raypilot ...

Eli Lilly and Incyte's Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,000 ...